Center for Drug Clinical Research, Shanghai University of Chinese Medicine, Shanghai, P.R. China.
Curr Drug Metab. 2013 Jun;14(5):605-15. doi: 10.2174/13892002113149990002.
The amount of drug remaining after previous doses, or drug accumulation, is closely related to drug efficacy and safety. An accurate calculation of the accumulation index or ratio (R(ac)) is crucial for dose finding. However, in drug accumulation studies little consensus exists with regard to experimental design or data analysis. We conducted a systematic review of the literature to produce a detailed profile of drug accumulation studies of the last 30 years (1980-2011). Ninety-six articles comprising 122 studies were analyzed. A typical drug accumulation study enrolled 10 to 20 subjects randomly assigned into treatment groups of 1 or 2 dose levels to observe pharmacokinetic behaviors. The median washout period between single and multiple dosing was 7 days, and the dose interval was 1-2 elimination half-lives in non- or one-compartmental models. Generally, the number of repeated times of administration for multiple dosing was 7-14, and the median number of sampling time points was 11. Eight different methods were used to calculate R(ac). The most frequently used method, in 72.9% of the studies, was to set R(ac) equal to the ratio of the area under a plasma concentration-time curve (AUC) during a dosage interval at steady state to the AUC of a dosage interval after the first dose, i.e., R(ac) = AUC(0-τ,ss) / AUC(0-τ,1). The values of R(ac) in the included studies ranged from 0.85 to 18.8, and 68.03% were <2. We suggest that sample size estimation for an accumulation study should be similar to that of a bioequivalence study, and in most studies, 18-24 subjects will be needed. Appropriate calculation methods for R(ac) should be selected based on the experimental design and data characteristics. The crucial values for non-, weak, moderate, and strong accumulation can be set at R(ac) < 1.2, 1.2 ≤ R(ac) < 2, 2 ≤ R(ac) < 5, and R(ac) ≥ 5, respectively. Accumulations studies should also give more regard to drug metabolism and increased accumulation in kidney or liver damaged patients.
先前剂量后剩余的药物量,或药物蓄积,与药物疗效和安全性密切相关。准确计算蓄积指数或比(R(ac))对于剂量发现至关重要。然而,在药物蓄积研究中,对于实验设计或数据分析几乎没有共识。我们对文献进行了系统回顾,以详细描述过去 30 年(1980-2011 年)的药物蓄积研究概况。分析了 96 篇文章,共 122 项研究。典型的药物蓄积研究纳入了 10 至 20 名受试者,随机分配到 1 或 2 个剂量水平的治疗组,以观察药代动力学行为。单剂量和多剂量之间的平均洗脱期为 7 天,非一室或单室模型的剂量间隔为 1-2 个消除半衰期。一般来说,多剂量给药重复次数为 7-14 次,中位数采样时间点为 11 个。有 8 种不同的方法用于计算 R(ac)。在 72.9%的研究中,最常用的方法是将 R(ac)定义为稳态时一个剂量间隔内的血浆浓度-时间曲线(AUC)与首次剂量后一个剂量间隔的 AUC 的比值,即 R(ac) = AUC(0-τ,ss) / AUC(0-τ,1)。纳入研究中 R(ac)的值范围为 0.85 至 18.8,68.03%<2。我们建议蓄积研究的样本量估计应与生物等效性研究相似,在大多数研究中,需要 18-24 名受试者。应根据实验设计和数据特征选择合适的 R(ac)计算方法。非、弱、中、强蓄积的关键值可分别设定为 R(ac) < 1.2、1.2 ≤ R(ac) < 2、2 ≤ R(ac) < 5 和 R(ac) ≥ 5。蓄积研究还应更多地关注药物代谢以及在肾脏或肝脏受损患者中蓄积增加的问题。